Patient Clinical Trials

See All Mercy Clinical Trials ›

Currently Displaying: Active Clinical Trials

Hide
Trial Status

A-13181-000

Topic of Study: Lung Cancer
Sponsor: Evidera
Principal Investigator: Sandy Kotiah, M.D., 410-783-5858
Research Coordinator: Lisa McConnell, RN, 410-332-1200 and Sarah Ruff, RN, 410-332-9459
For More Information: 410-951-7950
Coordinated Through: Prevention & Research Center

The purpose of this study is to understand experiences with an NSCLC condition and to evaluate two questionnaires that ask participants about these symptoms. 

All Comers (GO29436)

Topic of Study: Lung Cancer
Sponsor: F HoffmanLa Roche
Principal Investigator: Sandy Kotiah, M.D., 410-783-5858
Research Coordinator: Lisa McConnell, RN, 410-332-1200 and Sarah Ruff, RN, 410-332-9459
For More Information: 410-951-7950
Coordinated Through: Prevention & Research Center

The purpose of this study is to compare MPDL3280A carboplatin and paclitaxel versus MPDL3280A plus carboplatin, paclitaxel and bevacizumab versus carboplatin, paclitaxel, and bevacizumab without MPDL3280A in chemotherapy‑naïve patients with stage IV non-squamous non-small cell lung cancer (Clinicaltrials.gov ID#: NCT02366143).

BYL719

Topic of Study: Breast Cancer
Sponsor: Novartis Pharmaceuticals Corporation
Principal Investigator: David A. Riseberg, M.D., 410-783-5858
Research Coordinator: Lisa McConnell, RN, 410-332-1200 and Sarah Ruff, RN, 410-332-9459
For More Information: 410-951-7950
Coordinated Through: Prevention & Research Center

This is a placebo controlled trial evaluating Letrozole with or without BYL719 or Buparlisib, for the neoadjuvant treatment of postmenopausal women who are hormone receptor-positive and HER2/Neu negative. (Clinicaltrials.gov ID#: NCT01923168 )

A Single Arm Prospective Multicenter Study Evaluating the Biodesign® Plastic Surgery Matrix

Topic of Study: Breast Cancer
Sponsor: Cook Biotech Incorporated
Principal Investigator: Brendan J. Collins, M.D., 401-332-9700
Research Coordinator: Irene van Gaalen, PA-C, 410-332-5488
For More Information: 410-951-7950
Coordinated Through: The Breast Reconstruction and Restoration Center at Mercy

This study is designed for patients desiring nipple reconstruction following surgery for breast cancer and breast reconstruction. Eligible patients will receive a surgical procedure to reconstruct one or both nipples utilizing the COOK® Biodesign® Plastic Surgery Matrix. The study is designed to evaluate the benefit of this device in achieving effective and aesthetic nipple reconstruction. Patients will be evaluated at the time of the procedure and at 1 week, 4 weeks, 3 months, 6 months, and 12 months after surgery to examine the projection of their reconstructed nipple(s) and patient satisfaction (Cook Medical Study 09-009; Clinicaltrials.gov ID#: NCT01216319).

GO29527

Topic of Study: Lung Cancer
Sponsor: F HoffmanLa Roche
Principal Investigator: Sandy Kotiah, M.D., 410-783-5858
Research Coordinator: Lisa McConnell, RN, 410-332-1200 and Sarah Ruff, RN, 410-332-9459
For More Information: 410-951-7950
Coordinated Through: Prevention & Research Center

The purpose of this study is to compare the efficacy and safety of MPDL3280A versus standard of care in patients with Stage IB−Stage IIIA non-small cell lung cancer following resection and adjuvant chemotherapy. (Clinicaltrials.gov ID#: NCT02486718)

Hormone Therapy With or Without Everolimus in Treating Patients with Breast Cancer

Topic of Study: Breast Cancer
Sponsor: Southwest Oncology Group
Principal Investigator: David A. Riseberg, MD, 410-783-5858
Research Coordinator: Lisa McConnell, RN, 410-332-1200 and Sarah Ruff, RN, 410-332-9459
For More Information: 410-951-7950
Coordinated Through: Prevention & Research Center

This randomized phase III trial is studying how well giving hormone therapy together with or without everolimus works in treating patients with high-risk, hormone receptor-positive, HER2-negative breast cancer. (SWOG S1207, ClinicalTrials.gov ID#: NCT01674140)

IMpassion

Topic of Study: Breast Cancer
Sponsor: F HoffmanLa Roche
Principal Investigator: David A. Riseberg, M.D., 410-783-5858
Research Coordinator: Lisa McConnell, RN, 410-332-1200 and Sarah Ruff, RN, 410-332-9459
For More Information: 410-951-7950
Coordinated Through: Prevention & Research Center

The purpose of this study is to compare MPDL3280A plus nab‑paclitaxel versus placebo plus nab-paclitaxel  for patients with previously untreated metastatic triple‑negative breast cancer (Clinicaltrials.gov ID#: NCT02425891).

Insulin

Topic of Study: Breast Cancer
Sponsor: Mt Sinai NY
Principal Investigator: Neil B. Friedman, M.D., 410-332-9330
Research Coordinator: Lisa McConnell, RN, 410-332-1200; Sarah Ruff, RN, 410-332-9459 and Andrea Gerbasio CRA, 410-951-7908
For More Information: 410-951-7950
Coordinated Through: Prevention & Research Center

This study is researching the link between insulin resistance and breast cancer prognosis in African American and Caucasian women.

KATHERINE

Topic of Study: Breast Cancer
Sponsor: F HoffmanLa Roche
Principal Investigator: David A. Riseberg, MD, 410-783-5858
Research Coordinator: Lisa McConnell, RN, 410-332-1200 and Sarah Ruff, RN, 410-332-9459
For More Information: 410-951-7950
Coordinated Through: Prevention & Research Center

This phase III study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab (also known as Herceptin®) as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in the breast or axillary lymph nodes following preoperative therapy. (Roche BO27938 / NSABP B-50-I / GBG 77, ClinicalTrials.gov ID#: NCT01772472)

Observational Study to Define the Microbiologic and Immune Characteristics of Peritoneal Tissues in Patients with Appendiceal Cancer with Peritoneal Spread

Topic of Study: Appendiceal Cancer
Principal Investigator: Armando Sardi, MD, FACS, 410-332-9294
Research Coordinator: Michelle Sittig, RN, 410-783-5828
For More Information: 410-332-9294
Coordinated Through: Surgical Oncology at Mercy

The primary aim of the study is to determine the microbiological environment of the peritoneal tissues of patients undergoing cytoreductive surgery with intraoperative hyperthermic chemotherapy for appendix cancer with peritoneal spread.

Olympia

Topic of Study: Breast Cancer
Sponsor: NRG Oncology
Principal Investigator: David A. Riseberg, MD, 410-783-5858
Research Coordinator: Lisa McConnell, RN, 410-332-1200 and Sarah Ruff, RN, 410-332-9459
For More Information: 410-951-7950
Coordinated Through: Prevention & Research Center

This trial compares olaparib versus placebo as adjuvant treatment in patients with BRCA1 or BRCA2 mutations and triple negative breast cancer (ClinicalTrials.gov ID#: NCT02032823)

PROMIS

Topic of Study: Breast Cancer
Sponsor: Agendia
Principal Investigator: David A. Riseberg, MD, 410-783-5858
Research Coordinator: Lisa McConnell, RN, 410-332-1200 and Sarah Ruff, RN, 410-332-9459
For More Information: 410-951-7950
Coordinated Through: Prevention & Research Center

This is a prospective, observational study that will assess the impact of MammaPrint on treatment decisions (chemotherapy plus endocrine versus endocrine alone) in patients with an intermediate score by Oncotype DX®.  MammaPrint is an FDA-cleared test that may be used to identify which early-stage breast cancer patients are at risk of distant recurrence following surgery. (Clinicaltrials.gov ID#: NCT01617954)

SOLAR-1

Topic of Study: Breast Cancer
Sponsor: Novartis Pharmaceuticals Corporation
Principal Investigator: David A. Riseberg, M.D., 410-783-5858
Research Coordinator: Lisa McConnell, RN, 410-332-1200 and Sarah Ruff, RN, 410-332-9459
For More Information: 410-951-7950
Coordinated Through: Prevention & Research Center

The purpose for the study is to learn whether alpelisib, when added to fulvestrant, helps to reduce the growth of breast cancer cells in people with hormone receptor-positive, HER2-negative advanced breast cancer. (Clinicaltrials.gov ID#: NCT02437318)

Sophia

Topic of Study: Breast Cancer
Sponsor: Macrogenics
Principal Investigator: David A. Riseberg, M.D., 410-783-5858
Research Coordinator: Lisa McConnell, RN, 410-332-1200 and Sarah Ruff, RN, 410-332-9459
For More Information: 410-951-7950
Coordinated Through: Prevention & Research Center

The purpose of this study is to compare standard chemotherapy plus margetuximab compared to standard chemotherapy plus Herceptin® for women with metastatic or locally-advanced HER2-positive breast cancer that has progressed following two standard treatments for their cancer.

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients with Invasive RxPONDER Breast Cancer

Topic of Study: Breast Cancer
Sponsor: Southwest Oncology Group
Principal Investigator: David A. Riseberg, MD, 410-783-5858
Research Coordinator: Lisa McConnell, RN, 410-332-1200 and Sarah Ruff, RN, 410-332-9459
For More Information: 410-951-7950
Coordinated Through: Prevention & Research Center

The objective of this phase III clinical trial is to determine the effect of endocrine therapy with or without chemotherapy in patients with node-positive breast cancer who do not have high Recurrence Scores (RS) by Oncotype DX®.  (SWOG S1007, Clinicaltrials.gov ID#: NCT01272037)

TARGIT-US

Topic of Study: Breast Cancer
Sponsor: University of California San Francisco
Principal Investigator: Neil B. Friedman, MD, 410-332-9330
Study Coordinator: Andrea Gerbasio, 410-951-7908
For More Information: 410-951-7950
Coordinated Through: Prevention & Research Center

This is an observational study for women who are receiving Intraoperative Radiation Therapy (IORT) following breast-conserving surgery. (ClinicalTrials.gov ID#: NCT01570998)